## Methylxanthines: Mechanism of Action **Key Point:** Methylxanthines (theophylline, aminophylline) work by inhibiting phosphodiesterase (PDE), which prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to sustained bronchodilation and additional anti-inflammatory effects. ### Mechanism Comparison: Methylxanthines vs Beta-2 Agonists | Feature | Methylxanthines | Beta-2 Agonists | | --- | --- | --- | | **Primary mechanism** | PDE inhibition → ↑ cAMP | β2 receptor agonism → ↑ cAMP | | **Onset of action** | Slow (30–60 min) | Rapid (5–15 min) | | **Duration** | Long (8–12 hours) | Short to long (4–12 hours) | | **Therapeutic index** | Narrow (toxic at high levels) | Wide | | **Additional effects** | Respiratory stimulation, diuresis, CNS stimulation | Minimal extra-pulmonary effects | ### Pathway Detail ```mermaid flowchart LR A[Adenylyl cyclase activated]:::action --> B[cAMP production]:::outcome C[Phosphodiesterase]:::action --> D[cAMP breakdown]:::outcome B --> E[Smooth muscle relaxation]:::outcome D --> F[Loss of bronchodilation]:::outcome G[Methylxanthines]:::action -->|Inhibit| C H[Beta-2 agonists]:::action -->|Activate| A ``` **High-Yield:** Theophylline has a narrow therapeutic window (10–20 μg/mL). Levels >20 μg/mL cause toxicity: nausea, vomiting, arrhythmias, seizures. Many drug interactions (CYP1A2 substrate) — smoking, rifampicin, phenytoin induce metabolism; cimetidine, erythromycin inhibit it. **Clinical Pearl:** Methylxanthines also have mild anti-inflammatory effects and improve respiratory muscle contractility, making them useful in COPD. However, they are no longer first-line due to narrow therapeutic index and availability of safer alternatives. **Warning:** Do NOT confuse the mechanism — methylxanthines do NOT directly stimulate beta-2 receptors (that is the mechanism of beta-agonists). They work downstream by preventing cAMP degradation.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.